Howard Burris, MD, FACP, FASCO: How Oncology Biosimilars Will Impact Costs

Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses how oncology biosimilars will impact financial toxicity.
September 16, 2019


I don’t think there will be the drastic cost reduction that some people are hoping for that we see with some drugs, because it is complicated to make some of the biologics, to make the monoclonal antibodies. But I do think that will create some price pressure, that’ll create some alternatives.

On the flip side, I think one thing that often happens in that setting, it does motivate scientists, pharma, biotech, to come up with even better therapies. So hopefully, it’ll be a win-win solution: decreasing financial toxicity on one hand, and leading to even better therapies on the other.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.